Arbutus Biopharma Corp
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $14.1 | $6.2 | $18.1 | $39.0 | $11.0 |
| Operating income | -$38.2 | -$76.3 | -$78.1 | -$65.5 | -$73.5 |
| Net income | -$33.5 | -$69.9 | -$72.8 | -$69.5 | -$76.2 |
| Cash Flow Statement | |||||
| Free cash flow | -$39.6 | -$65.0 | -$86.9 | -$35.9 | -$68.3 |
Shares outstanding 197.5M · Free float 52.5%
Annual filing data through FY ended December 31, 2025; float as of August 30, 2026.